Clinical and Translational Radiation Oncology (Jan 2018)

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

  • Ben Fulton,
  • Susan C. Short,
  • Allan James,
  • Stefan Nowicki,
  • Catherine McBain,
  • Sarah Jefferies,
  • Caroline Kelly,
  • Jon Stobo,
  • Anna Morris,
  • Aoife Williamson,
  • Anthony J. Chalmers

DOI
https://doi.org/10.1016/j.ctro.2017.11.003
Journal volume & issue
Vol. 8, no. C
pp. 12 – 16

Abstract

Read online

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.

Keywords